Recombinant Sudan virus and evaluation of humoral cross-reactivity between Ebola and Sudan virus glycoproteins after infection or rVSV-ΔG-ZEBOV-GP vaccination
Markus H. Kainulainen, Jessica R. Harmon, Amy Whitesell, Éric Bergeron, Elif Karaaslan, Caitlin M. Cossaboom, Jason H. Malenfant, Aaron Kofman, Joel M. Montgomery, Mary J. Choi, César G. Albariño, Christina F. Spiropoulou
Abstract
Ebola disease outbreaks are major public health events because of human-to-human transmission and high mortality. These outbreaks are most often caused by Ebola virus, but at least three related viruses can also cause the disease. In 2022, Sudan virus re-emerged causing more than 160 confirmed and probable cases. This report describes generation of a recombinant Sudan virus and demonstrates its utility by quantifying antibody cross-reactivity between Ebola and Sudan virus glycoproteins after human infection or vaccination with a licensed Ebola virus vaccine.